The incidence rate of HER2 overexpression is reported with a wide range of 2.5%-34% in NSCLC, probably due to the inconsistency among different methods for positivity assessment and low concordance assessment by pathologists (9, 25–27). The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.